Related topics

Arcturus Therapeutics: 3Q Earnings Snapshot

November 9, 2020 GMT

SAN DIEGO (AP) _ Arcturus Therapeutics (ARCT) on Monday reported a loss of $21 million in its third quarter.

On a per-share basis, the San Diego-based company said it had a loss of 92 cents.

The results did not meet Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 47 cents per share.

The pharmaceutical company posted revenue of $2.3 million in the period, also missing Street forecasts. Six analysts surveyed by Zacks expected $3.2 million.

Arcturus Therapeutics shares have more than tripled since the beginning of the year. In the final minutes of trading on Monday, shares hit $34.39, more than tripling in the last 12 months.



This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ARCT at https://www.zacks.com/ap/ARCT